Bristol Myers Squibb announced positive interim Phase 3 results from the SUCCESSOR-2 study, marking the first successful Phase 3 trial for mezigdomide and the second positive Phase 3 outcome for the company's CELMoD program12
The combination treatment of oral mezigdomide with carfilzomib and dexamethasone (MeziKd) demonstrated statistically significant improvement in progression-free survival compared to carfilzomib and dexamethasone alone in patients with relapsed or refractory multiple myeloma12
Mezigdomide is a CELMoD agent (cereblon E3 ligase modulator) belonging to Bristol Myers Squibb's targeted protein degradation platform, developed over more than two decades12
The SUCCESSOR-2 study is a Phase 2/3, multicenter, randomized, open-label trial with progression-free survival as the primary endpoint and secondary endpoints including overall survival, overall response rate, and minimal residual disease negativity12
Bristol's stock has surged over 30% in the past six months, with UBS raising its price target to $70 and multiple analysts revising earnings estimates upward1
Data from SUCCESSOR-2 will be presented at a future medical meeting, with results to be shared with health authorities, though no specific regulatory submission timeline has been announced12
Sources:
1. https://ca.investing.com/news/company-news/bristol-myers-squibb-reports-positive-phase-3-trial-results-93CH-4502396
2. https://www.marketscreener.com/news/bristol-myers-squibb-announces-positive-phase-3-results-from-successor-2-study-of-oral-mezigdomide-i-ce7e5fdeda8cf52d